Acadia Healthcare (ACHC) Q3 2026 earnings review
Acadia Healthcare raises its profit plan, while state payments carry margins
Acadia Healthcare, the largest stand-alone operator of behavioral health hospitals in the US, grew sales and raised its full-year targets while underlying hospital profits dipped. Revenue from facilities open more than a year rose 5%, and lower construction spending produced $47 million in free cash flow by our math. Chief executive Debbie Osteen lifted the full-year profit plan, and put a $60 million target on the extra profit its 16 newest acute hospitals will add in 2027.
| Same-facility revenue | $883.2M +5.2% from a year ago |
|---|---|
| Adjusted EBITDA | $176.4M +2.0% from a year ago (-2.5% without extra Florida payment) |
| Free cash flow (by our math) | $47.2M net debt down to 3.9x Adjusted EBITDA |
| Full-year Adjusted EBITDA outlook | Raised $17.5M middle of the range: $620M (+1.8% from 2025) |
⚖️ Verdict: 🟢 Bullish
The story got better because management finally attached a 2027 dollar figure and a year to its new-hospital payoff while cutting debt to 3.9 times Adjusted EBITDA. One caution: third-quarter Adjusted EBITDA beat the company's plan only because a Florida state Medicaid payment came in $8 million above what the prior outlook assumed; without that extra payment, operating profit fell from a year ago.
The question now is whether the 6.6% rise in patient admissions will ever turn into matching patient-day growth, or whether shorter stays will keep soaking it up. Either new acute beds are simply replacing closed long-stay specialty beds, or insurers are forcing patients out of hospitals sooner. Fourth-quarter stay lengths and the 2027 outlook in February will settle it.
🐂 Bull Case
New Hospitals Get a 2027 Profit Target
Acadia has promised for three quarters that hospitals opened since 2023 would eventually add more than $200 million in annual profit, without saying when. Chief executive Debbie Osteen gave a dated step for the first time: "we now expect to deliver approximately $60 million of incremental EBITDA from these facilities in 2027 relative to 2026" across the 16 acute psychiatric hospitals opened over the last four years.
Meanwhile, the drag from newly opened and closed facilities stayed in check at $12.6 million in the third quarter, inside the $12 million to $14 million range management set in July. Putting a $60 million figure on 2027 matters because it replaces a timeless promise with a next-year target that investors can test against reported profit.
What to watch: the 2027 profit outlook when Acadia reports fourth-quarter results in February. If the full-year 2027 plan does not grow by at least $60 million over 2026, older hospitals are losing ground as the new ones fill up.
Lower Building Costs Lift Cash and Cut Debt
The behavioral healthcare provider has spent the year slowing down hospital construction to stop burning cash. In the third quarter, Acadia generated $97.9 million in operating cash flow and spent $50.7 million on capital expenditures, leaving $47.2 million in free cash flow by our math.
That cash allowed the company to pay down debt, lowering total debt on the balance sheet by $62.2 million from June to $2.35 billion and bringing net debt down to 3.9 times Adjusted EBITDA, from 4.1 times last quarter. Management also cut its full-year capital spending plan by another $25 million at the middle of the range, to $210 million to $230 million.
What to watch: fourth-quarter free cash flow, which the full-year outlook implies at about $12 million by our math. Holding net debt below 4.0 times Adjusted EBITDA at year-end will confirm the balance sheet has stabilised.
Acute Hospitals Carry Growth and Bed Additions
Acute inpatient psychiatric facilities — hospitals treating patients with urgent mental health crises — remain Acadia's main growth engine. Segment revenue rose 11.3% from a year ago to $524.8 million, as patient volumes grew 7.5%, "driven primarily by expanded capacity from both newly constructed and existing facilities", the company said.
Acadia added 220 licensed beds during the quarter, including a new 144-bed hospital near Jacksonville, Florida and 76 beds at existing hospitals. That brings nine-month additions to 542 beds by our math, already inside the full-year target of 500 to 600 beds with one quarter left.
What to watch: acute hospital volume growth in the fourth quarter as the construction pause takes hold. If volume growth slows sharply once new hospital openings stop, existing hospitals are not filling enough extra beds on their own.
Positives this quarter didn't test
Two standing drivers from earlier in the year got no new detail in the earnings release and await the conference call.
- Corporate overhead cuts: corporate general and administrative costs were $39.7 million, or 4.4% of revenue; the call will show whether the removal of middle management is yielding further savings.
- Using patient-outcome data in insurer rate talks: revenue per patient day rose 4.0% at existing hospitals, but part of that came from Florida state payments; commentary on commercial insurer rate renewals will test this on the call.
🐻 Bear Case
Florida State Payments Drove the Profit Beat
"Acadia delivered strong results in the third quarter, and our positive momentum is driving our increased full-year guidance," Osteen said. Yet the profit growth in the quarter came entirely from a larger-than-planned government payment accrual rather than hospital operations.
- Adjusted EBITDA (profit before interest, taxes, depreciation, and one-offs): $176.4 million, up $3.4 million or 2.0% from a year ago
- Florida supplemental Medicaid payment accrual: $13.4 million, versus $5.6 million in the prior outlook
- Adjusted EBITDA without the extra $7.8 million Florida benefit: $168.6 million, down 2.5% from a year ago by our math
- Salaries, wages, and benefits plus professional fees: up 1.0 percentage point of revenue from a year ago by our math
Hospital staffing costs and outside professional fees grew faster than revenue, squeezing operating margins even before counting legal expenses. Raising the full-year Adjusted EBITDA outlook by $17.5 million at the middle of the range after a $7.8 million Florida windfall leaves only about $10 million of raise from the rest of the business.
What to watch: fourth-quarter Adjusted EBITDA excluding any new state supplemental approvals, which the full-year outlook implies at about $150 million by our math. A drop below that level would show hospital margins are still shrinking against last year's clean fourth quarter.
Shorter Stays Keep Volume Growth Near 1%
At facilities Acadia has operated for more than a year, patient admissions rose 6.6% from a year ago, continuing the pace set in the first half. However, the average length of stay fell 5.1% to 14.4 days, so total patient days at those facilities grew only 1.1%.
Because insurers pay by the day, patient days are what drive revenue. Meanwhile, specialty treatment facility revenue fell 8.2% to $136.0 million "related to Specialty facilities in Pennsylvania and the impact from having closed several Specialty facilities over the last 12 months", where New York Medicaid has restricted out-of-state care.
What to watch: same-facility average length of stay in the fourth quarter, when Acadia laps the start of the shift toward shorter-stay acute beds. If length of stay keeps falling more than 4%, insurers are cutting approved hospital days rather than the shift coming purely from hospital mix.
Legal Bills Rebound and Medicaid Rules Tighten
Acadia faces ongoing Department of Justice and Securities and Exchange Commission investigations into its admission and billing practices, which the company leaves out of its adjusted profit metrics. Spending on government investigations jumped to $18.3 million in the third quarter, up from $7.5 million in the second quarter, bringing nine-month investigation costs to $38.2 million.
At the same time, the company warned that payments and patient volumes face risk from "significant changes to Medicaid financing mechanisms introduced by the One Big Beautiful Bill Act" and its "introduction of work or community engagement requirements in the Medicaid expansion population". Because Medicaid and state supplemental programs supply the majority of Acadia's revenue and this quarter's profit beat, tighter federal caps threaten its main profit source.
What to watch: the legal footnote in the third-quarter 10-Q filing for any loss reserve on federal investigations or the $105 million Fashion Valley jury verdict. Any cash settlement accrual would reduce the free cash flow earmarked for debt paydown.
Risks this quarter didn't answer
Three standing concerns from last quarter cannot be checked from the earnings release alone and depend on the upcoming 10-Q filing and conference call.
- Professional and general liability reserves: after $81.3 million of charges across the prior three quarters, the release shows no big spike in other operating expenses, but the reserve balance and claim trends sit in the 10-Q.
- Finance leadership stability: after changing chief financial officers twice in five quarters, the release quotes only Osteen; the call will show who is leading the finance team.
- Defense of inpatient care against outpatient alternatives: whether management addresses insurer pressure to move patients into outpatient clinics will be tested on the call.
💲 Other KPIs
Uncollected bills owed by insurers and government programs rose 6.5% from last quarter and 16.4% from a year ago by our math, growing more than three times as fast as third-quarter revenue (+5.1%). Part of that build reflects the $13.4 million Florida supplemental payment accrued during the quarter but not yet collected in cash.
Acadia's two smaller divisions moved in opposite directions. Comprehensive Treatment Centers — outpatient clinics treating opioid addiction — saw revenue dip 2.3% from a year ago to $141.1 million as the company opened one clinic and closed one. Residential Treatment Centers — longer-stay youth and behavioral facilities — grew revenue 6.7% to $93.4 million.
The diluted share count rose 1.3% from a year ago and 0.4% from last quarter, as employee stock compensation rose 53.3% to $9.2 million. The healthcare operator bought back no shares during the first nine months of 2026, keeping its remaining $250 million repurchase authorization on hold while paying down debt.
🔮 Guidance
Raised. The middle of the full-year sales plan moved up $25 million to $3.45 billion, or 4.1% growth from last year by our math. That leaves about $860 million for the fourth quarter, or 4.7% growth from a year ago — slightly slower than the third quarter's 5.1% pace. It is the second raise this year: $0M in April, +$15M in July, +$25M in November.
Raised. The middle of the range rose $17.5 million to $620 million, up 1.8% from 2025 by our math. That implies $150.1 million in the fourth quarter, up 50.4% against a year-ago quarter hit by a $52.7 million liability charge, but down 1.6% if that prior-year charge is excluded. It is the third raise this year: +$5M, +$5M, +$17.5M.
Raised. The middle of the profit-per-share outlook Excluding one-offs rose $0.225 to $1.75, which still sits 12.5% below 2025's $2.00 by our math. With $1.34 earned in the first nine months, the plan implies $0.41 per share in the fourth quarter, compared with $0.07 in the fourth quarter of 2025. It is the third raise in three quarters: +$0.05, +$0.05, +$0.225.
Raised. Acadia lifted the bottom of the range by $25 million, raising the middle by $12.5 million to $387.5 million. Because the group has already generated $321.5 million in the first nine months, the outlook implies $66.0 million in the fourth quarter by our math, down from $97.9 million in the third quarter. Three raises this year: +$5M, +$70M, +$12.5M.
Cut. The hospital operator lowered its full-year construction and equipment budget by $25 million at the middle of the range to $220 million, down 61.5% from last year's $571.8 million spend by our math. After spending $165.9 million in the first nine months, the plan leaves $54.1 million for the fourth quarter, slightly above the third quarter's $50.7 million. Moves this year: $0M, -$22.5M, -$25M.
❓ Key Questions
What are the revenue and profit of the 16 new hospitals today?
Osteen projected $60 million of extra profit in 2027 from the 16 acute hospitals opened over the last four years, but did not say what they earn now. Without the 2026 baseline, investors cannot tell how much is new profit versus disappearing startup losses.
Did the raised outlook include any Ohio supplemental Medicaid payments?
The third quarter included $13.4 million from Florida's payment program, $7.8 million above the prior plan. Management previously said Florida and Ohio programs under review could add over $20 million; how much remains unbooked for the fourth quarter?
Why did government investigation costs more than double from last quarter?
Legal and advisory spending on federal investigations rose from $7.5 million in the second quarter to $18.3 million in the third. Is the Department of Justice or Securities and Exchange Commission inquiry entering a more active phase?
How much of the 5.1% drop in patient stay length is insurer pushback?
Same-facility admissions rose 6.6%, but shorter stays held patient-day growth to 1.1%. Can management separate the mathematical effect of opening short-stay acute beds from insurers cutting approved inpatient days at existing acute hospitals?